<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25179">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064114</url>
  </required_header>
  <id_info>
    <org_study_id>PV4300</org_study_id>
    <nct_id>NCT02064114</nct_id>
  </id_info>
  <brief_title>SORT - AF Supervised Obesity Reduction Trial for AF Ablation Patients</brief_title>
  <acronym>SORT-AF</acronym>
  <official_title>Supervised Obesity Reduction Trial for AF Ablation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis:

      Weight reduction in obese patients with atrial fibrillation. Obese patients benefit from an
      obesity treatment after atrial fibrillation ablation.

      Study design:

      A prospective randomized, open-lable clinical trial.

      Study protocol:

      The purpose of this study is to proof a professional care of overweight patients with
      symptomatic atrial fibrillation, as well as the treatment of the risk factors for atrial
      fibrillation, especially obstructive sleep apnea and hypertension.

      There is a 1:1 randomization. In the intervention group, patients are followed up in a
      6-month intensive care after atrial fibrillation ablation. During the follow up time
      patients will visit the nutritional advice every two weeks for 6 months.

      The Follow-up in the control group is standard of care. At baseline,  a screening test for
      obstructive sleep apnea and arterial hypertension will be performed as standard care.

      The documentation of atrial fibrillation after ablation is made possible by the implantation
      of an event recorder before atrial fibrillation ablation.

      Follow up:

      A follow-up will be performed after 3,6 and 12 months in both groups. Patients in the
      intervention group will be followed-up every 2 weeks in the first 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recurrence of sustained atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recurrence of sustained atrial fibrillation (&gt;30 seconds) after atrial fibrillation ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coincidence of sleep apnea</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Obesity</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional treatment, followed for a period of 3,6 and 12 months after the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intervention group</intervention_name>
    <description>Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>Followed for a period of 3,6 and 12 months after the procedure.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Overweight with a BMI ≥ 30

          -  Obtained written informed consent

          -  Symptomatic atrial fibrillation with indication for ablation

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Permanent atrial fibrillation (failed Cardioversion or episode duration &gt; 12 months)

          -  Previous surgical or interventional therapy of atrial fibrillation

          -  BMI &gt; 40

          -  Pregnant women or women of childbearing potential without a negative pregnancy test
             within 48 hours prior to treatment

          -  History of hemorrhagic diathesis or other coagulopathies

          -  Contraindications for oral anticoagulation

          -  Hyper- or hypothyroidism

          -  Drug or chronic alcohol abuse

          -  Has any condition that would make participation not be in the best interest of the
             subject

          -  Incompliants

          -  Unable to perform athletic exercise due to disease or disability

          -  Resident outside Hamburg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Willems</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Willems</last_name>
    <phone>+ 49 40 7410</phone>
    <phone_ext>59471</phone_ext>
    <email>willems@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nele Gessler</last_name>
      <phone>+ 49 40 7410</phone>
      <phone_ext>59471</phone_ext>
      <email>n.gessler@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Katrin Fuerst</last_name>
      <phone>+ 49 40 7410</phone>
      <phone_ext>59471</phone_ext>
      <email>k.fuerst@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan Willems</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMI &gt;40</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
